;

HANG TEN

;

Ganoderma Microsporum Immunomodulatory Protein, GMI

GMI is a fungal immunomodulatory protein that has multiple immunomodulatory properties. It was tested by the National Cancer Institute’s (NCI) anticancer drug screen with 56 human tumor cell lines, the National Institute of Health (NIH), US, under the registration number 767593, and was found to be effective in the suppression of cancer cell growth. It is also known as MM767593.

Several MM767593-related patents have been issued:

．Taiwan patent I299735
An immunomodulatory protein cloned from Ganoderma microsporum


．US patent US7601808
An immunomodulatory protein cloned from Ganoderma microsporum


MM767593 has been extensively investigated by researchers from the National Taiwan University, Yang-Ming University, Chung Shan Medical University and the Industrial Technology Research Institute.
Results show that MM767593 possesses functions of anti-cancer, anti-inflammation, immunomodulation and blood sugar regulation, etc.

．Taiwan patent I414307
New Uses of an immunomodulatory protein (GMI) from Ganoderma microsporum

．US patent US8476238
Uses of an immunomodulatory protein (GMI) from Ganoderma microsporum

Oncology Study

The results from the NIH show the promising potential of MM767593 in the development of new protein drugs against cancers.


(click to enlarge)

Blood Sugar Regulation

Both in vitro and in vivo studies performed by the National Taiwan University show that giving mice 0.8 mg of MM767593 per day improves blood sugar regulation, lowers triglyceride storage in the liver, and also has limited anti-inflammatory effects, indicating a great potential of MM767593 in product development.

Cheers!!!  MycoMagic partners with Ganoherb Technology of Fujian, China to tap the vast mainland Chinese market.

...more

;